RGC
Regencell Bioscience Holdings Ltd
NASDAQ: RGC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$28.95
-0.34% today
Updated 2026-04-29
Market cap
$14.32B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.01
Dividend yield
—
52W range
$2 – $84
Volume
0.1M
Regencell Bioscience Holdings Ltd (RGC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-54.80%
ROA
-33.20%
Debt/equity
0.11x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $2.52B | $91.00M | 96.18% | 10.69% | 3.62% |
| 2007 | $2.60B | $86.00M | 96.00% | 11.86% | 3.31% |
| 2008 | $2.66B | $363.00M | 96.13% | 12.10% | 13.64% |
| 2009 | $2.77B | $72.00M | 96.17% | 10.25% | 2.60% |
| 2010 | $2.89B | $95.50M | 60.02% | 10.83% | 3.30% |
| 2011 | $2.81B | $77.60M | 96.40% | 7.69% | 2.76% |
| 2012 | $2.68B | $40.30M | 96.42% | 8.25% | 1.50% |
| 2013 | $2.82B | $144.80M | 96.42% | 11.83% | 5.13% |
| 2014 | $3.04B | $157.70M | 96.35% | 11.18% | 5.19% |
| 2015 | $2.99B | $105.60M | 96.29% | 10.25% | 3.53% |
| 2016 | $3.13B | $153.40M | 61.39% | 10.84% | 4.91% |
| 2017 | $3.20B | $170.40M | 61.63% | 10.77% | 5.33% |
| 2018 | $3.16B | $112.30M | 96.11% | 8.59% | 3.55% |
| 2019 | $0.00 | $-390990.00 | — | — | — |
| 2020 | $0.00 | $-812371.00 | — | — | — |
| 2021 | $0.00 | $-1.35M | — | — | — |
| 2022 | $0.00 | $-7.42M | — | — | — |
| 2023 | $0.00 | $-5.87M | — | — | — |
| 2024 | $0.00 | $-4.30M | — | — | — |
| 2025 | — | $-3.58M | — | — | — |